The NOICH Study.
Completed
- Conditions
- Fetal or Neonatal Alloimmune Thrombocytopenia
- Registration Number
- NL-OMON21014
- Lead Sponsor
- Sanquin Bloodbank Amsterdam provides the trial medication
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 212
Inclusion Criteria
1. Pregnant women with a subsequent pregnancy after prior pregnancy complicated by HPA alloimmunization who have given birth to a child with a platelet count < 150 x 10 9/l in the first week of life;
2. HPA alloimmunization must have been confirmed by the presence of maternal anti-HPA antibodies and the offending HPA antigen in the fetus or homozygous partner;
Exclusion Criteria
1. Pregnant women with autoimmune thrombocytopenia;
2. Twins or multiple pregnancies;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of neonates with intracranial hemorrhage.
- Secondary Outcome Measures
Name Time Method Cord blood platelet count at birth.<br /><br>Other variables studied will be the levels of maternal and neonatal anti-HPA antibodies and IgG, the occurrence of other bleedings in the neonate as well as the necessity and type of neonatal treatment.